pyrazinamide

Pyrazinamide is a small molecule antituberculosis agent used as part of combination therapy for the treatment of active tuberculosis. It is a prodrug that is converted by the bacterial enzyme pyrazinamidase into its active form, pyrazinoic acid, within Mycobacterium tuberculosis. The primary mechanism involves disruption of membrane energetics and inhibition of membrane transport function in M. tuberculosis, particularly under acidic conditions found at infection sites[2][5][6]. Pyrazinoic acid may also trigger degradation of aspartate decarboxylase PanD, blocking synthesis of coenzyme A and thereby inhibiting bacterial survival[5]. Pyrazinamide is not generally recommended for latent TB but plays a crucial role in shortening the duration of therapy for active disease when used with other agents such as rifampicin and isoniazid[1][3][8].

Brand names

TebrazidPyrazinamide

Other names

pyrazinamid2-carbamylpyrazine2-pyrazinecarboxamideAldinamidePirazinamidaPirazinamidePyrazinamidumPyrazine carboxamidepyrazine–2-carboxamidePyrazineamidePyrazinecarboxamidePyrazinoic acid amidePyrizinamide